Autoimmune response to advanced glycosylation end-products of human LDL

Gabriel Virella,‡ Suzanne R. Thorpe,† Nathan L. Alderson,† Elias M. Stephan,§ Daniel Atchley,‡§ Maria F. Lopes-Virella,§ and the DCCT/EDIC Research Group

Department of Microbiology and Immunology,§ Medical University of South Carolina, Charleston, SC 92425; Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208; and Department of Medicine,§ Division of Endocrinology-Metabolism-Nutrition, Medical University of South Carolina, Charleston, SC 92425

Abstract Advanced glycosylation end-products (AGEs) are believed to play a significant role in the development of vascular complications in diabetic patients. One such product, AGE-LDL, has been shown to be immunogenic. In this report, we describe the isolation and characterization of human AGE-LDL antibodies from the sera of seven patients with Type 1 diabetes by affinity chromatography using an immobilized AGE-LDL preparation that contained primarily the AGE Nε(carboxymethyl)lysine (CML, 14.6 mmol/mol lysine), and smaller amounts of Nε(carboxyethyl)lysine (CEL, 2.7 mmol/mol lysine). The isolated antibodies were predominantly IgG of subclasses 1 and 3, and considered proinflammatory because of their ability to promote FcγR-mediated phagocytosis and to activate complement. We determined dissociation constants (Kd) for the purified antibodies. The average Kd values (4.76 ± 2.52 × 10^-9 mol/l) indicated that AGE-LDL antibodies are of higher avidity than oxidized LDL antibodies measured previously (Kd = 1.53 ± 0.7 × 10^-9 ml/l), but of lower avidity than rabbit polyclonal LDL antibodies (Kd = 9.34 × 10^-11). Analysis of the apolipoprotein B-rich lipoproteins isolated with polyethylene glycol-precipitated antigen-antibody complexes from the same patients showed the presence of both CML and CEL, —Virella, G., S. R. Thorpe, N. L. Alderson, E. M. Stephan, D. Atchley, F. Wagner, M. F. Lopes-Virella, and the DCCT/EDIC Research Group. Autoimmune response to advanced glycosylation end-products of human LDL. J. Lipid Res. 2003. 44: 487–493.

Supplementary key words modified lipoproteins • diabetes • immunogenicity of advanced glycosylation end-products-LDL • advanced glycosylation end-products-LDL antibodies

It is well known that diabetes mellitus is associated with an increased incidence of macrovascular complications, including coronary heart disease, cerebrovascular disease, and peripheral vascular disease (1–3). The mechanisms by which diabetes accelerates atherosclerosis are not well understood. It has been proposed that an increased level of chemically modified lipoproteins might be a significant factor contributing to the accelerated development of macrovascular complications in diabetes (2). The persistence of high plasma glucose levels in diabetic individuals creates favorable conditions for some of these modifications to occur, including glycosylation, glycoxidation (2), and advanced glycosylation (3).

Advanced glycosylation involves a chain of chemical reactions that starts with the covalent, nonenzymatic addition of reducing sugars to protein amino groups (Schiff base, Amadori adducts). If the half-life of a protein is sufficiently long, additional reactions take place, leading to the formation of a heterogeneous family of sugar-amino acid adducts collectively known as advanced glycosylation end-products (AGEs) (5). LDL, like all plasma proteins, is susceptible to AGE modification (4). A variety of potentially pathogenic consequences can be linked to AGE modification of LDL, including direct or indirect induction of proinflammatory circuits (4–6), as well as trapping of protein in atherosclerotic plaques (5). In addition, AGE-modified proteins are immunogenic (7), a property that has been used to great advantage for their detection in serum (2) and localization in tissues (2, 8).

The immunogenicity of AGE-modified proteins is not limited to the induction of heterologous antibodies in experimental animals. Autoantibodies to AGE-modified serum albumin and AGE-modified IgG have been demon-
strated in human sera, both from diabetic patients as well as in nondiabetic subjects (9–11). Data suggesting that these antibodies are able to combine with circulating AGE-modified antigens and form soluble immune complexes (ICs) have also been recently reported (10).

Of particular importance would be the demonstration that AGE-LDL is immunogenic, given the considerable wealth of evidence suggesting that LDL-ICs may play a significant pathogenic role in atherosclerosis (12, 13). LDL-ICs containing oxidized LDL (oxLDL) have been demonstrated in atherosclerotic lesions (14, 15), and studies with model ICs prepared with human LDL and rabbit antibodies have shown that LDL-ICs cause foam cell formation and activate the release of proinflammatory cytokines and matrix metalloproteinases (16–18). Similar properties have also been demonstrated for polyethylene glycol (PEG)-precipitated ICs containing LDL obtained from the sera of diabetic patients (19, 20).

Our group has characterized in detail antibodies reacting with oxLDL isolated from the sera of patients with diabetes and nondiabetic subjects. Those antibodies are predominantly of the IgG isotype restricted to the proinflammatory subtypes 1 and 3 (21, 22). OxLDL antibodies have a moderate $K_d (1.1 \pm 1.05 \times 10^{-8} \text{ mol/l})$, and cross-reactivity studies showed that they react primarily with malondialdehyde (MDA)-lysine epities (23). In this report, we describe the isolation and characterization of AGE-LDL antibodies isolated from seven Type 1 diabetic subjects and the results of experiments aimed at defining the nature of the immunogenic modifications that elicit autoantibody formation. This, to our knowledge, is the first report of the isolation and characterization of human autoantibodies to AGE-LDL.

MATERIALS AND METHODS

Sera

The sera from 13 patients with Type 1 diabetes were used as the source of purified AGE-LDL antibodies and modified lipoproteins coprecipitated with antigen-antibody complexes. The serum samples were obtained as part of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Complication (DCCT/EDIC) study at participating EDIC centers. The EDIC study is a continuation of the DCCT study involving patients from the original DCCT cohort who joined the EDIC study. The primary goal of EDIC is to study the development of macrovascular disease in Type 1 diabetes. A collaborative project (Markers and Mechanisms for Macrovacular Disease in insulin-dependent diabietes mellitus) between the Medical University of South Carolina and the DCCT/EDIC Group has as its primary goal the identification of new markers, risk factors, and mechanisms for macrovascular disease in Type 1 diabetes. A secondary goal is to relate putative vascular risk factors to microvascular complications (retinopathy and nephopathy) since it was hypothesized that common mechanisms of vascular damage may be implicated. Informed consent as approved by the Institutional Review Board for Human Research of every Center involved in the DCCT/EDIC trial was obtained from each subject included in this study.

Isolation of LDL and AGE-modification of isolated LDL

Blood was collected in 0.4 mM EDTA after a 12 h fast. LDL was isolated from individual or pooled plasma after density adjust-

ment ($1.019 < d < 1.063 \text{ g/ml}$) with potassium bromide (KBr) by preparative ultracentrifugation at 50,000 rpm for 17 h on a Beckman L-80 ultracentrifuge using a type 70 Ti rotor (19). The isolated LDL was washed by ultracentrifugation, dialyzed against a 0.15 mol/l sodium chloride solution containing 0.5 mM EDTA, pH 8.0, then was passed through an Acrodisc 0.2 μm filter in order to sterilize and remove aggregates, and stored under nitrogen in the dark at 4°C.

AGE-LDL was prepared by a modification of the method described by Schmidt et al. (24). Freshly isolated LDL at a 1.2 mg/ml concentration was sterilized by passage through a 0.2 μm filter added to 150 mM glucose-6-phosphate in 200 mM phosphate buffer, pH 7.8, containing 40 μM butyldihydroxyethylene (BHT) and 540 μM EDTA, filter-sterilized a second time, and incubated for 8 weeks at 37°C. At the end of the incubation, the LDL solution was dialyzed for 8 h against two changes of 4 liters of 0.15 M NaCl, 0.3 mM EDTA, pH 8.0. The dialyzed AGE-LDL was filter-sterilized a second time, the final protein concentration determined by the Lowry assay (25), and stored in the dark at 4°C.

Analysis of LDL modification

Analysis of purified lipoproteins for their content of (carboxymethyl)lysine (CML), (carboxyethyl)lysine (CEL), and the advanced lipoxidation end-products (ALEs) MDA- and 4-hydroxynonenal (HNE)-lysine was carried out by isotope dilution selected-ion-monitoring gas chromatography-mass spectrometry (SIM-GC-MS) as described by Requena et al. (3). Briefly, these four AGE/ALEs were measured simultaneously in LDL (0.4 mg protein) after borohydride reduction of the protein. The reduced sample was dialyzed, dried, delipidated [chloroform-methanol (2:1, v/v), containing 0.02% BHT], and following addition of heavy labeled internal standards, hydrolyzed at 110°C in 6 N HCl for 18 h. The hydrolysate was dried, passed over a 1 ml solid phase extraction C8-column (Sep-pak, Waters, Milford MA) to remove brown products formed during hydrolysis, dried again, and then amino acids derivatized as their trifluoroacetyl methyl esters for analysis by SIM-GC-MS (1–3). All modified amino acids are expressed as a ratio to the parent amino acid, lysine.

Preparation of Sepharose-AGE LDL and isolation of AGE-antibodies

AGE-LDL was coupled to Sepharose using a modification of the method previously described by us for preparation of oxLDL-Sepharose (19, 23). AGE-LDL was dialyzed against coupling buffer (0.1 M NaHCO3 + 0.5 M NaCl, pH 8.3) overnight at 4°C, mixed and incubated with activated Sepharose (2 g), and prepared according to the manufacturer’s instructions (Amersham-Pharmacia Biotech, Piscataway, NJ) at a protein-dry gel ratio of 12.5 mg/g. Coupling was allowed to proceed at 4°C overnight on an end-over-end mixer. Free reactive sites remaining on the Sepharose gel were blocked with 0.1 M Tris buffer, pH 8.0, and, after extensive washing and degassing, the gel suspension (7 ml) was transferred to a chromatography column and washed thoroughly with 0.01 M NaHCO3 pH 8.3 buffer.

AGE-LDL antibodies were isolated from 1 ml aliquots of patient sera diluted in 3 ml of 0.01 M NaHCO3 pH 8.3 buffer. The diluted serum was loaded at room temperature into the AGE-LDL-Sepharose column. The column was incubated overnight at 4°C, and the unbound protein was washed off with 0.01 NaHCO3 pH 8.3 buffer at room temperature. The bound antibody was eluted with 0.1 M NaHCO3 buffer, pH 8.0, containing 0.5 M NaCl, and the protein-containing fractions were tested by enzyme immunoassay (EIA) to confirm the presence of AGE-LDL antibodies. A second elution of the AGE-Sepharose column with 0.2 M glycine-HCl, pH 2.3, did not yield additional proteins, but was always carried out to regenerate the column.
Characterization of the purified human
AGE-LDL antibodies

EIA. AGE-LDL antibody activity was measured by a modification of the EIA originally described for the measurement of ox-LDL antibodies (23, 26). Immulon type 1 plates (Dynatech Laboratories Inc, Chantilly, VA) were coated with 7.5 μg of AGE-LDL per well. Peroxidase-labeled rabbit anti-human IgG (light and heavy chain specific, ICN Biochemicals Inc, Costa Mesa, CA) was used to detect captured antibodies. The difference between the optical density (OD) measured at 414 nm with unabsorbed and adsorbed samples was considered as reflecting antibody concentration, expressed in OD Units.

Antibody avidity. An estimate of the avidity of each purified antibody was obtained through the measurement of Kd by competitive enzyme immunoassay using a modification of Friguet’s method (27), as adapted to the characterization of ox-LDL antibodies by Mironova et al. (19). Flat-bottomed Immulon Type I plates were coated with 7.5 μg of AGE-LDL per well. Purified AGE-LDL antibody was used at a final concentration of 100 μg/ml. A series of antibody aliquots was absorbed using concentrations of AGE-LDL ranging from 7.36 × 10⁻⁷ to 1.15 × 10⁻⁸ M. The concentrations of antigen along with the absorbance values measured in unabsorbed and absorbed samples were used to construct a plot of v/a versus v where v corresponds to bound antibody and v/a to bound antibody/free antigen at equilibrium (27). The slope of the plot was used to calculate the Kd.

Immunoglobulin isotypes. The distribution of immunoglobulin isotypes in the fractions eluted from the AGE-LDL column was determined by measuring IgG (total and subclasses 1, 2, 3, and 4), IgM, and IgA by radial immunodiffusion (RID) using low-level RID kits purchased from The Binding Site Inc., San Diego, CA.

Cross-reactivity. To determine whether AGE-LDL antibodies cross-react with oxLDL or native LDL, we performed EIA in which the plates were coated with AGE-LDL, and 200 μl aliquots of purified antibodies were absorbed with 200 μl of AGE-LDL, oxLDL, or native LDL at a concentration of 200 μg/ml. An identical volume of buffer was added to an unabsorbed aliquot of the same antibodies. To determine whether unrelated serum proteins share the CML epitope(s) of LDL, we prepared CML-modified LDL and human serum albumin (HSA) at similar levels of modification, (5 mmol CML/mol lysine for LDL and 4 mmol CML/mol lysine for HSA). Each of these preparations (80 μg), as well as identical concentrations of the unmodified counterparts and of a preparation of AGE-LDL prepared as described earlier, were added to dilutions of four different purified AGE-LDL antibodies. The antibody dilutions were adjusted so that the OD (414 nm) of the unabsorbed samples reacting with AGE-LDL in the EIA varied between 0.6 and 1.0. The differences in OD measured with unabsorbed and absorbed aliquots by EIA were considered indicative of the reactivity of the antibodies with the different modified LDL preparations.

Isolation of LDL and IgG precipitated with 3.5% PEG

To better define the nature of LDL modifications responsible for the immune response that results in the formation of LDL-IC, we characterized the modifications of LDL precipitated as LDL-IC with 3.5% PEG from the serum of seven diabetic patients (20, 28). The sera were selected based on the previous detection of cholesterol and apolipoprotein B (apoB) in 3.5% PEG precipitates (29). To isolate the LDL moiety of LDL-IC, we precipitated serum aliquots with 3.5% PEG and fractionated the resuspended precipitates by affinity chromatography on Protein G-Sepharose (Amersham-Pharmacia). The column was washed with 0.1 M sodium phosphate buffer, pH 8.3, containing 0.5 M NaCl. Under these conditions, IgG antibodies of all specificities and subclasses remained bound to the column while non-IgG antibodies and antigens (including lipoproteins) were contained in the wash-out. The wash-out was next fractionated by affinity chromatography on a heparin-agarose column (Sigma-Aldrich Corp., St. Louis, MO) that retained apoB-containing lipoproteins, while all other antigens and antibodies were eliminated in the flow-through fraction. The lipoprotein-containing samples were pooled and diazylzed against saline containing 0.3 mM EDTA, pH 8.0. Protein content was measured by the Lowry reaction (25) and AGE-ALE content quantified by SIM-GCMS as described above.

RESULTS

AGE-LDL antibodies were isolated from the sera of seven patients with Type 1 diabetes mellitus. These patients were selected from a group of 1,026 EDIC patients screened for AGE-LDL antibodies (Fig. 1). In the total population, the median concentration of AGE-LDL antibody was 0.211 OD units (range: 0 to 0.898). The patients were selected based on their high concentration of AGE-LDL antibodies and sample availability. The median concentration of AGE-LDL antibody in the samples chosen for isolation of AGE-LDL antibodies was 0.588 OD units (range: 0.477-0.761). Table 1 shows that the purified AGE-LDL antibodies were predominantly of the IgG isotype, more specifically of the IgG1 and IgG3 subclasses. In some sera, IgM antibodies were detected in relatively large concentrations, although always lower than those of IgG antibodies. The Kd values varied between 0.76 to 8.1 × 10⁻⁹ mol/l (average 4.76 ± 2.52 × 10⁻⁹ mol/l).

The AGE-LDL preparation used to prepare the affinity chromatography column used to purify AGE-LDL antibodies contained primarily CML (14.6 mmol/mol lysine) and smaller amounts of CEL (2.7 mmol/mol lysine), but no detectable MDA- or HNE-lysine (Table 2). The results suggest that under the conditions used in our laboratory to prepare AGE-modified LDL, the two major glycoxidation products, CML and CEL, were formed in high amounts.

![Fig. 1. Distribution of advanced glycosylation end-products (AGE)-LDL antibody levels in 1,026 blood samples studied as part of the Epidemiology of Diabetes Complication (EDIC) protocol](https://example.com/fig1.jpg)
and there was minimal lipid oxidation. Therefore, the purified AGE-LDL antibodies should recognize CML and CEL epitopes.

To obtain a better understanding of the nature of LDL modifications recognized by human autoantibodies, we used an alternative strategy that consisted in isolating and characterizing the lipoproteins involved in spontaneous formation of IC. The analysis of the coprecipitated lipoproteins (Fig. 2) showed the presence of CML, CEL, and MDA-lysine, suggesting that a mixture of antibodies to oxidized lipoproteins, recognizing MDA-lysine epitopes, and to AGE-modified lipoproteins, recognizing CML and CEL modifications, must have been involved in IC formation.

Finally, we carried out two studies to define the specificity of our purified AGE-LDL antibodies. In the first study (Fig. 3A), we compared the reduction in reactivity of purified AGE antibodies with AGE-LDL caused by preincubation with AGE-LDL, oxLDL, and native (unmodified) LDL. The preincubation with AGE-LDL resulted in a significantly higher reduction in reactivity with AGE-LDL than the preincubation with either native or oxLDL. To determine whether CML was a major epitope recognized by AGE-LDL antibodies and whether the epitopes associated with CML are identical in different proteins, we compared the reduction in reactivity with AGE-LDL of four different AGE-LDL antibodies caused by preincubation with AGE-LDL, CML-LDL, and CML-HSA (Fig. 3B). The results showed that the reductions in reactivity caused by preincubation with AGE-LDL or CML-LDL were not significantly different, while a significant difference was observed between samples preincubated with CML-LDL and CML-HSA, suggesting that the CML-lysine epitopes are not identical in unrelated proteins.

### DISCUSSION

The pathogenesis of macrovascular disease in diabetes mellitus has received considerable attention as a consequence of the increased incidence of macrovascular complications in diabetic patients, including coronary heart disease, cerebrovascular disease, and peripheral vascular disease (30). In recent years, atherosclerosis has been defined as a chronic inflammatory process (31). The definition of factors that may trigger the inflammatory process is of obvious importance, and immunologic mechanisms, both cell mediated (32–34) and antibody mediated (12, 15, 35, 36), have been proposed as playing that role. The involvement of antigen-antibody complexes formed by modified lipoproteins and corresponding antibodies in the pathogenesis of atherosclerosis is supported by the fact that those complexes have both proinflammatory and atherogenic properties (16, 18, 37–39), and by epidemiologic associations between immune complex levels and an increased risk for the development of coronary heart disease (13, 40).

Diabetic patients would appear to be at particular risk for the development of IC involving modified lipoproteins because chronic hyperglycemia leads to protein glycosylation. Glycosylated proteins, including LDL, are more susceptible to oxidation (41, 42). The synergy of glycosylation and oxidation results in the formation of AGE or glycoxidation products such as CML and CEL (43, 44).

### TABLE 1. Characteristics of AGE-LDL antibodies isolated from the sera of seven patients with Type 1 diabetes by affinity chromatography on AGE-LDL-Sepharose columns

| Sample | Total IgG | IgG1 | IgG2 | IgG3 | IgG4 | IgM | IgA | $K_d$ ($\times 10^{-9}$) |
|--------|-----------|------|------|------|------|-----|-----|----------------------|
| A      | 23.2      | nd   | nd   | nd   | 12.9 | 1.6 |     | 4.80                 |
| B      | 52.5      | 28.1 | 9.9  | 14.5 | 4.8  | 0.9 |     | 6.80                 |
| C      | 32.2      | 16.1 | nd   | 6.1  | nd   |     |     | 8.09                 |
| D      | 48.9      | 23.2 | 7.5  | 18.2 | 12.9 | 3.5 |     | 0.76                 |
| E      | 38.9      | 20.7 | nd   | 18.2 | 26.6 | 2.2 |     | 4.52                 |
| F      | 26.0      | 11.5 | nd   | 14.5 | 11.2 | 4.5 |     | 2.45                 |
| G      | 92.6      | 58.6 | 4.0  | 30.0 | nd   |     |     | 5.92                 |

The levels of the four IgG subclasses, IgA, and IgM were determined by radial immunodiffusion. The total IgG concentration was calculated by adding the concentrations of the four IgG subclasses. Dissociation constants ($K_d$) were determined by enzymoimmunoassay (EIA).

### TABLE 2. Advanced glycosylation and advanced lipoxidation end-products (ALE) content of apoB-containing lipoproteins isolated from polyethylene glycol (PEG)-precipitated immune complexes (ICs). Masked samples of bound (closed bars) and unbound (hatched bars) fractions from the heparin-agarose column, as well as native LDL (open bars), were analyzed by selected ion-monitoring gas chromatography/mass spectrometry (SIM-GC-MS) for their content of (carboxymethyl)lysine (CML), (carboxyethyl)lysine (CEL), and malondialdehyde (MDA)-lysine; 4-hydroxynonenal (HNE)-lysine ions were monitored but not detected in any samples. The values are expressed as mean ± SEM (n = 6).

| Protein Preparation | CML | CEL | MDA-Lysine | HNE-Lysine |
|---------------------|-----|-----|------------|------------|
| AGE-LDL (n = 2)     | 13.8–15.5$^a$ | 2.7–2.7$^b$ | nd         | nd         |
| Native LDL (n = 3)  | 0.15–0.16  | 0.03–0.04 | nd         | nd         |

$^a$ Values expressed in mmol/mol lysine.

$^b$ Data are range of values for indicated number of samples.
Both oxLDL and AGE-modified proteins have been proven to be immunogenic (45–47), and autoantibodies to oxLDL and to AGE-modified proteins have been described (10, 48). The existence of circulating ICs containing AGE-modified proteins was also recently reported by Turk et al. (10). However, the evidence for the existence of antibodies to AGE-modified proteins and ICs formed by AGE-modified proteins and the corresponding antibodies is based on the use of AGE-albumin. No direct evidence for the existence of autoantibodies reacting with AGE-modified lipoproteins has been published.

The AGE-LDL autoantibodies we have isolated from the sera of patients with diabetes mellitus are remarkable for their relative homogeneity in isotype distribution and avidity. The predominance of IgG1 and IgG3 is similar to what had been previously observed with isolated oxLDL antibodies, but the average avidity of AGE-LDL antibodies is higher than that of oxLDL antibodies. This is an important observation, because it implies that AGE-LDL antibodies have the required characteristics to form stable IC likely to interact with and activate inflammatory cells (22).

To define the immunogenic modifications associated with AGE-LDL formation, we used several different approaches. The identification of CML and CEL as major modifications in the AGE preparations used to prepare the AGE-LDL immunoadsorbant columns suggested that the autoantibodies would recognize CML and CEL epitopes. However, other important epitopes may not have been present in AGE-LDL prepared in vitro. To further clarify this issue, we isolated apoB-rich lipoproteins (including LDL) from the supernatant and precipitates obtained after incubation of sera from diabetic subjects with 3.5% PEG by affinity chromatography in heparin-Sepharose. This concentration of PEG is known to precipitate IC but not soluble antigens or antibodies (49, 50). We have also established that soluble, native LDL is only precipitated in vestigial amounts by 3.5% PEG (20). The finding of an enrichment of CML, CEL, and MDA-lysine in the precipitated lipoproteins allows two conclusions. First, it supports the data obtained in the analysis of the AGE-LDL used to prepare the immunoadsorbant pointing to CML and CEL as the major modifications recognized by AGE-LDL autoantibodies. Second, it suggests that diabetics have multiple autoantibodies to different forms of modified LDL, including AGE-LDL and oxLDL. The residual reactivity of purified AGE-LDL antibodies with nLDL may be explained by the presence of spontaneously formed AGE-LDL in LDL isolated from normal donors, while the reactivity with oxLDL is likely to result from the generation of CML-lysine during copper oxidation. Both possibilities are supported by findings reported in a previous report of our studies on the isolation and characterization of oxLDL antibodies. Freshly isolated LDL was found to contain measurable concentrations of CML-lysine, which increased 3- to 15-fold after copper oxidation for 19 h (23).

One question that remained to be answered was whether antibodies to CML-modified proteins are able to recognize any type of AGE-modified protein. Crystallographic studies of defined antigen-antibody complexes suggest that that would not be the case, because even if the CML group is the immunodominant structure recognized by AGE-protein antibodies, the epitopes are defined not only by the immunodominant determinant, but also by the 15–22 amino acids in its immediate vicinity (51). The likelihood that these amino acids would be distributed and folded in identical spatial arrangements in proteins as different as albumin and apoB appears highly
unlikely. The fact that preparations of CML-LDL were able to decrease the reactivity of purified AGE-LDL antibodies, but identically modified CML-albumin preparations were ineffective, proves that AGE-protein antibodies are specific for different AGE-modified proteins. As such, the detection of AGE antibodies using AGE-modified albumin as substrate does not prove that antibodies to AGE-LDL are present in the same patient. This is important in the context of the relationship of AGE antibodies and macrovascular disease, because we have proven in previous studies that IC involving proteins other than LDL do not share the atherogenic properties of LDL-IC (16).

APPENDIX

Participants of the DCCT/EDIC Research Group

Albert Einstein College of Medicine: H. Shamon, H. Duffy, S. Engel, and H. Engel; Case Western Reserve University: S. Gethum (study co-chairman), W. Dahms, L. Mayer, S. Pendegras, H. Zegarra, D. Miller, and L. Singerman; Cornell University Medical Center: D. Brillon, M. Lackaye, M. Heinemann, F. Rahhal, V. Reppuci, and T. Lee; Henry Ford Health System: F. Whitehouse, D. Kruger, and J. D. Carey; International Diabetes Center: R. Bergenthal, M. Johnson, D. Kendall, M. Spencer, D. Noller, K. Morgan, and D. Etzwiler; Joslin Diabetes Center: A. Jacobson, E. Golden, D. Soroko, G. Sharuk, P. Arrigg, and J. Doyle; Massachusetts General Hospital: D. Nathan (study co-chairman), S. Fritz, J. Godine, C. McKittrick, and P. Lou; Mayo Foundation: J. Service, G. Ziegler, and J. Pach; Medical University of South Carolina: J. Colwell, D. Wood, R. Mayfield, K. Hermayer, M. Szpiech, T. Lyons, J. Parker, A. Farr, S. Elsing, and T. Thompson; Northwestern University: M. Molitch, B. Schaaf, L. Jampol, D. Weinberg, and A. Lyon; University of California, San Diego: O. Koltermann, G. Lorenzi, and M. Goldbaum; University of Iowa: W. Stivitz, M. Bayless, R. Zeithier, T. Weingeist, E. Stone, H. Culver, B. C. Gehie, and S. Russell; University of Maryland School of Medicine: D. Countis, A. Kowarski, D. Ostrowski, T. Donner, S. Stiehl, and B. Jones; University of Michigan: W. Herman, D. Greene, C. Martin, M. J. Stevens, A. K. Vine, and S. Elner; University of Minnesota: J. Bantle, B. Rogness, T. Olsen, E. Steuer, and S. Kaushel; University of Missouri: D. Goldstein, S. Hitt, J. Giangiacomo, and L. D. Ormerod; University of New Mexico: D. Schade, J. Canady, M. Schluster, A. Das, and D. Hornbeck; University of Pennsylvania: S. Schwartz, B. J. Maschak-Carey, L. Baker, and S. Brautenstein; University of Pittsburgh: T. Orchard, N. Silvers, T. Songer, D. Doft, S. Olson, R. L. Bergren, and M. Fineeman; University of South Florida: J. Malone, H. Wetz, C. Berger, R. Gstalder, and P. R. Pavan; University of Tennessee: M. Byer-Ash, A. Katabchi, H. Lambeth, M. B. Murphy, S. Moser, and D. Meyer; University of Texas Southwestern University Medical Center: P. Raskin, S. Strowig, A. Edwards, J. Alappatt, C. Wilson, and S. Park; University of Toronto: B. Zinnman, A. Barnie, S. MacLean, R. Devenyi, M. Mandelcorn, and M. Breen; University of Washington: J. Palmer, S. Catton, J. Kinyoun, and L. Van Oortgham; University of Western Ontario: J. Dupre, J. Harth, C. Canny, and D. Nicolle; Vanderbilt University: M. May, R. Lorenz, J. Lipps, L. Suvant, S. Feman, and Tawansy; Washington University, St. Louis: N. White, J. Santiago, L. Levandowski, I. Bonik, G. Grand, M. Thomas, D. Burgess, D. Joseph, and K. Blinder; Yale University School of Medicine: W. Tamborlane, P. Gatcomb, and K. Stroesel; Clinical Coordinating Center (Case Western Reserve University): B. Dahms, R. Trail, and J. Quin; Data Coordinating Center (The George Washington University, Biostatistics Center): J. Lachin, P. Cleary, D. Kenny, J. Backlund, A. Henry, K. Klump, and D. Lamas; Molecular Risk Factors Program Project (Medical University of South Carolina): W. T. Garvey, T. J. Lyons, A. Jenkins, R. Klein, M. Lopes-Virella, G. Virella, A. A. Jaffa, D. Zheng, D. Lackland, D. McGee, and R. K. Mayfield.

The research reported in this publication was supported by a project grant cofunded by the National Institutes of Health/NHLBI (PO1-HL55782), the Juvenile Diabetes Foundation International, the Research Service of the Ralph H. Johnson Department of Veteran Affairs Medical Center (M. F. L.V.), and by grants from the USPHS DK19971, and the Juvenile Diabetes Research Foundation (JDRF-1-2000-6663) (S.T. and N.L.A.). The DCCT/EDIC was sponsored through research contracts from the Division of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institutes of Health. Additional support was provided by the National Center for Research Resources through the GCRC program, and by Genentech, Inc. through a Cooperative Research and Development Agreement with the NIDDK.

The authors wish to acknowledge the assistance of Dr. Deyi Zheng with statistical analysis, and the expert technical assistance of Heather Lampinen. The authors also wish to thank Drs. Saul Gethum and Orville Koltermann for their valuable criticisms of the manuscript.

REFERENCES

1. Fu, M. X., J. R. Requena, A. J. Jenkins, T. J. Lyons, J. W. Baynes, and S. R. Thorpe. 1996. The advanced glycation end product, Nεl-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycation reactions. J. Biol. Chem. 271: 9982–9986.
2. Onorato, J. M., S. R. Thorpe, and J. W. Baynes. 1998. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann. N. Y. Acad. Sci. 854: 277–290.
3. Requena, J. R., M. X. Fu, M. U. Ahmed, A. J. Jenkins, T. J. Lyons, J. W. Baynes, and S. R. Thorpe. 1997. Quantification of malondialdehyde- and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoproteins. Biochem. J. 322: 317–325.
4. Schmidt, A. M., O. Horii, J. X. Chen, J. F. Li, J. Crandall, J. Zhang, R. Cao, S. D. Yan, J. Brett, and D. Stern. 1995. Advanced glycation end-products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96: 1895–1403.
5. Schmidt, A. M., S. D. Yan, S. F. Yan, and D. M. Stern. 2001. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108: 945–955.
6. Vlassara, H., R. Bucala, and L. Striker. 1994. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 70: 138–151.
7. Ikeda, K., R. Nagai, T. Sakamoto, H. Sano, T. Araki, N. Sakata, H. Nakayama, M. Yoshida, S. Ueda, and S. Horiiuchi. 1998. Immunoochemical approaches to AGE-structures: characterization of anti-AGE antibodies. J. Immunol. Methods. 215: 95–104.
8. Nakamura, Y., Y. Horii, T. Nishino, H. Shiiki, Y. Sakaguchi, T. Kagoshima, K. Dohi, Z. Makita, H. Vlassara, and R. Bucala. 1993. Immunochemical localization of advanced glycosylation end-products in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143: 1649–1656.
9. Lucey, M. D., M. M. Newkirk, C. Neville, K. Lepage, and P. R. Fortin. 2000. Association between IgM response to IgG damaged by glycoxidation and disease activity in rheumatoid arthritis. J. Rheumato. l. 27: 319–323.
10. Turk, Z., S. Ljubic, N. Turk, and B. Benko. 2001. Detection of au-
to antibodies against advanced glycation end-products and AGE-immune complexes in serum of patients with diabetes mellitus. *Clin. Chim. Acta.* **303:** 102–115.

21. Griffith, R. L., G. T. Virella, H. C. Stevenson, and M. F. Lopes-Virella. 1988. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. *J. Exp. Med.* **168:** 1041–1059.

22. Hansson, G. K. 1999. Inflammation and immune response in atherosclerosis. *Curr. Atheroscler. Rep.* **1:** 150–153.

23. Emeson, E. F., and A. L. J. Robertson. 1988. T lymphocytes and coronary intima: Their potential role in atherogenesis. *Am. J. Pathol.* **130:** 369–376.

24. Steinbrecher, U. P., M. Fisher, J. L. Witztum, and L. K. Curtiss. 1994. Rabbit and human atherosclerotic lesions: The Framingham study. *JAMA.* **261:** 2035–2038.

25. Ross, R. 1999. Atherosclerosis—An inflammatory disease. *N. Engl. J. Med.* **340:** 115–126.

26. Friguet, B., G. Virella, and G. T. Virella. 1998. The immunology of atherosclerosis. In *Diabetes Annual,* S. M. Marshall, P. D. Home, and R. A. Rizza, R.A., editors. vol. 11. Elsevier, Amsterdam. 81–95.

27. Friguet, B., G. Allochis, C. Cusaro, R. Rolla, E. Mottaran, G. Bellomo, and E. Albano. 2000. Antibodies against advanced glycation end product Nε-(carboxymethyl)lysine in healthy controls and diabetic patients. *Diabetologia.* **43:** 1385–1388.

28. Helft, S. W., G. M. Rosenfeld, S. Parthasarathy, T. E. Carew, S. Butler, J. L. Witztum, and D. Steinberg. 1981. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. *J. Clin. Invest.* **84:** 1086–1095.

29. Atchley, D. H., M. F. Lopes-Virella, D. Zheng, and G. Virella. 2002. Oxidized LDL-immune complexes and diabetic nephropathy. *Diabetologia.* **45:** 1562–1571.

30. Kannel, W. B., and D. L. McGee. 1979. Diabetes and cardiovascular disease. The Framingham study. *JAMA.* **241:** 2035–2038.

31. Ormoneit, M. A., R. L. Klein, G. T. Virella, and M. F. Lopes-Virella. 1996. Modification of LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. *Clin. Immunol.* **90:** 165–172.

32. Lopes-Virella, M. F., and G. Virella. 1998. The immunology of atherosclerosis. In *Diabetes Annual,* S. M. Marshall, P. D. Home, and R. A. Rizza, R.A., editors. vol. 11. Elsevier, Amsterdam. 81–95.

33. Virella, G. 2001. Phagocytic cells. In *Medical Immunology.* 5th edition. G. Virella, editor. Marcel Dekker, New York. 245–258.

34. Steinbrecher, U. P., M. Fisher, J. L. Witztum, and L. K. Curtiss. 1994. Rabbit and human atherosclerotic lesions: The Framingham study. *JAMA.* **261:** 2035–2038.

35. Hansson, G. K., G. Bondjers, A. B. Brinck, and L. Hjalmarsson. 1980. Ultrastructural studies on the localization of IgG in the aortic endothelium and subendothelial intima of atherosclerotic and non-atherosclerotic rabbits. *Exp. Mol. Pathol.* **33:** 302–315.

36. Paruns, D., and M. J. Mitchinson. 1981. Demonstration of immunoglobulin in the neighborhood of advanced atherosclerotic plaques. *Atherosclerosis.* **38:** 211–216.

37. Gisinger, C., G. T. Virella, and M. F. Lopes-Virella. 1991. Erythrocyte-bound low-density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocyte-derived macrophages. *Clin. Immunol. Immunopathol.* **59:** 37–52.

38. Kilmon, A. N., A. D. Denisenko, A. G. Vinogradov, V. A. Nagorov, Y. I. Pivocarova, O. D. Sinikova, and V. M. Pleskov. 1988. Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody immune complex. *Atherosclerosis.* **74:** 41–46.

39. Orekhov, A. N., and V. V. Tertov. 1990. Antibody-like immunoglobulins G against low density lipoprotein that stimulate lipid accumulation in cultured cells. *In Hypercholesterolemia, Hypercholesterolemia,* E. C. L. Mailander, editor. Plenum Press, New York. 399–404.

40. Orchard, T. J., G. Virella, K. J. Forrest, R. W. Evans, D. J. Becker, and M. F. Lopes-Virella. 1999. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. *Diabetes.* **48:** 1454–1458.

41. Lopes-Virella, M. F., R. L. Klein, and G. Virella. 1996. Modification of lipoproteins in diabetes. *Diabetes Metab. Rev.* **12:** 69–90.

42. Mullarkey, C. J., D. Edelstein, and M. Brownlee. 1999. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. *Biochem. Biophys. Res. Commun.* **173:** 932–939.

43. Baynes, J. W. 1991. Role of oxidative stress in development of complications in diabetes. *Diabetes.* **40:** 405–412.

44. Baynes, J. W., and S. R. Thorpe. 2000. Glycoxidation and lipoxidation in atherogenesis. *Free Radic. Biol. Med.* **28:** 1708–1716.

45. Hansson, G. K. 1999. Inflammation and immune response in atherosclerosis. In *Diabetes Annual,* S. M. Marshall, P. D. Home, and R. A. Rizza, R.A., editors. vol. 11. Elsevier, Amsterdam. 81–95.

46. Emeson, E. F., and A. L. J. Robertson. 1988. T lymphocytes in atherosclerotic lesions of euglycemic rabbits. *Exp. Mol. Pathol.* **45:** 32–40.

47. Palinski, W., S. Yla-Herttuala, S. W. Butler, S. A. Sadosky, R. Parthasarathy, L. K. Curtiss, and J. L. Witztum. 1999. Antiserum and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. *Atherosclerosis.* **109:** 325–335.

48. Polinski, W., T. Koschinsky, S. W. Butler, E. Miller, H. Vlassara, A. Cerami, and J. L. Witztum. 1995. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. *Atherosclerosis. Thromb. Vasc. Biol.* **15:** 571–582.

49. Steinbrecher, U. P., M. Fisher, J. L. Witztum, and L. K. Curtiss. 1984. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carboxylation: generation of antibodies specific for derivatized lysine. *J. Lipid Res.* **25:** 1109–1116.

50. Shibayama, R., N. Araki, R. Nagai, and S. Horiuichi. 1999. Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction. *Diabetes.* **48:** 1842–1849.

51. Kilpatrick, J. M., A. L. J. Robertson, K. Y. Forrest, and G. Virella. 1995. Validation of the PG-εLpG screening test for soluble immune complexes by longitudinal studies in experimental acute serum sickness. *J. Clin. Lab. Immunol.* **17:** 79–84.

52. Virella, G., J. M. Kilpatrick, F. Chenais, and H. H. Fudenberg. 1981. Isolation of soluble immune complexes from human serum: Combined use of polyethylene glycol precipitation, gel filtration, and affinity chromatography on protein A-Sepharose. *Methods Enzymol.* **74:** 641–668.

53. Virella, G. 2001. Phagocytic cells. In *Medical Immunology,* 5th edition. G. Virella, editor. Marcel Dekker, New York. 245–258.